StemCell Therapy

What happened

Healthcare stocks, on balance, had a great start to the week today. Cancer companies in particular posted strong gains almost across the board Monday. For instance, the stock ofClovis Oncology(NASDAQ:CLVS)ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of 10.2% before ultimately closing up by 8.5%, and Puma Biotechnology(NASDAQ:PBYI)printed a 16.3% gain today.

The odd part to this rising-tide phenomenon is that none of these companies issued a single press release or market-moving Securities and Exchange Commission filing Monday. Instead, this sea of green appears to be the result of institutional investors fleeing weaker parts of the market like oil in favor of safe havens like healthcare. Cancer stocks, after all, should be essentially immune to the economic impacts of the COVID-19 pandemic, given that most patients can't skip out on lifesaving treatments.

Image Source: Getty Images.

If this flight-to-safety thesis is true, then Clovis, Immunomedics, and Puma would arguably all make outstanding vehicles to gain exposure to the high-growth oncology space. Each of these stocks is grossly undervalued relative to its long-term value proposition. Wall Street's 12-month price targets on these names underscore this point nicely. Even after today's sizable moves, for instance, Clovis, Immunomedics, and Puma are still trading well below their 12-month price targets.

Why are these three cancer stocks undervalued right now? Clovis and Puma have both struggled to gain the confidence of investors in this volatile market due to the uncertain commercial outlook for their flagship cancer meds. Immunomedics, on the other hand, scored a major late-stage trial win with itstriple-negative breast cancer drug candidate sacituzumab govitecan earlier this year. Even so, the company's stock has yet to truly price in the full value of this positive clinical outcome, presumably because of the unfavorable market conditions in general.

Are these suddenly red-hot biotech stocks still worth buying? In a word, yes. Clovis should grab an important label expansion for its ovarian cancer med Rubraca later this year, a pivotal event that has the potential to be an inflection point for the company's commercial operations.

Puma, on the other hand, still looks like a decent buy based on the long-term commercial prospects of its breast cancer med Nerlynx. The drug's sales have been slowed down by its onerous side-effect profile, but it should nevertheless still achieve at least $300 million in annual sales. Puma's market cap, by contrast, is only $440 million at the time of this writing.

And Immunomedics stands out as a fantastic buyout target. Triple negative breast cancer is a high-value indication for which few drugs have panned out in clinical studies. Immunomedics, in turn, should fetch a healthy tender offer if sacituzumab govitecan does indeed get the green light from regulators.

See original here:
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today - The Motley Fool

When you talk about biotechnology, some of the things that come to mind might be the Resident Evil series, Westworld, or even the Spider-man series. However, its something pretty real, and its a pretty big thing across the world.

To put it simply, biotechnology istechnology based on biology, where cellular and bio-molecular elements are used to develop technologies and products that can potentially improve our daily lives. For example, biotechnology is used to come up with medical vaccines and cures, like what theyre doing with finding a cure for the Covid-19 pandemic now.

And Malaysias apparently been paying quite a lot of attention to expand the field in the country for the last several years; were sometimes even called the biotechnology hub in Asia. And at one point in time in Malaysia

In 2003, when the 8th Malaysia Plan was announced by Dr. Mahathir Mohamad, he announced a plan to develop a BioValley as well. It was a proposal to build a localbiotechnology center in Cyberjaya, or more specifically, in Dengkil. The project served as one of the final initiatives in Mahathirs last days as our fourth Prime Minister.

While it may seem that the biotechnology buzz had just hit Malaysia around that time, it was said that our government had already identified it as one of the five key technologies to help transform Malaysia into a highly developed nation in the 1980s. According to Mahathir, this BioValley would be a 15km by 50km hard-wired zone thats intended to be a location for biotechnology innovation. Apparently, the Malaysian government at the time was hoping that the plan could attract USD$10billion in foreign and local investments within 10 years.

To develop the BioValley, our government decided to not just work with the Japanese for the architecture, but also the Massachusetts Institute of Technology (MIT). MIT had apparently recommended the BioValley focus on research into agriculture and natural resources, given that these are what we have a lot of.

Im confident we can build a multibillion dollar biotechnology industry in Malaysia. All the ingredients are here. We are just working on the recipe. MIT professor Anthony Sinskey, as quoted by The Wall Street Journal

Working together with MIT, the initial plan of the BioValley was to situate it in Dengkil with three research institutes, costing around USD$160million. And it was expected to complete in 2005. However

GIF from Gifimage.net

However, after the announcement in 2003, the plan was shrouded in mystery, where hardly anyone, especially the media, could get any details about it. For example, we didnt know anything about the progression of the project or at what stage it was in. Part of the reason behind the secrecy was said to be due to lessons learned from MSC, which didnt garner as much investment as the government had initially hoped, and the government wascautioned against overselling the BioValley project.

We want to get the project off the ground rather than talk about it. An official at the Science, Technology and Environment Ministry, as quoted by Nature

What we do know is that apparently, there were already three companies that had agreed to park themselves in the BioValleyin 2003, and the government was in the process of negotiating with another 20. Not just that, while it was still in planning stages, researchers were already tapping into our countrys resources, such as looking into tongkat ali to treat, um, certain disabilities in men.

Following the announcement of the BioValley in 2003, Mahathir resigned and Abdullah Ahmad Badawi took over as our fifth Prime Minister, so essentially, he took over the project as well.

However, the expected completion date of 2005 cameand went. Until today, theres still nothing to show for the BioValley. There currently are no photos or anything of the BioValley that was supposedly to be already under development.

Now, there are different verdicts about the BioValley project. Some have claimed that its still under development, some said that its never existed, while others just dont want to talk about it. We dont even know for sure where the USD$160million that was supposed to go into the project had gone to. All thats left is apparently an 80-hectare construction site with a few empty buildings in Dengkil, but even then, theres no pictures of the site.

One had even called it

It was one of the most grandiose biotechnology projects. We were hoping that BioValley would take off. University of Malaya Research & Innovation Assistant Vice-Chancellor Rofina Yasmin Othman, as quoted by Malaysian Business

But thats not to say that weve completely failed in our biotechnology ventures as

Image from EduSpiral

While the BioValley kinda didnt pan out, we still have a pretty strong presence within the industry. Malaysia was ranked fourth globally for Biotech Enterprise Support in the Scientific American Report and second in ASEAN for intellectual property protection in the IMD World Competitiveness Index Yearbook.

Plus, our government launched aNational Bioeconomy Programmein 2010, making Malaysia the first in Southeast Asia to have such an initiative. The main objectives were to focus on specific bio-based industries in Malaysia in order turn Malaysia into a high-income nation bywell, this year, actually.

In fact, biotechnology has become so important in Malaysia that we came up with our Biosafety Act to regulate the release, importation, exportation and contained use of living modified organisms, and the release of products of such organisms. And that also made us one of the few Asian countries to be activelymanaging and assessing the risks that come with biotechnology.

And when we talk about the BioValley, while the BioValley in Dengkil doesnt seem to be operational any time soon, wedohave a BioValley of a smaller scale in Miri, Sarawak, funded by the Sarawak government.

Its not the same thing as the one in Dengkil, but hey, at least its something! Its a collaboration between the Sarawak government and Curtin University. Just like the plan for the initial BioValley in Dengkil, this ones meant to support the development and research of biotechnology, while also providing jobs.

The Sarawak Biovalley Pilot Plant is unique because it aims to assess and maximise the viability of bio-products for commercial production. Curtin University Malaysia pro vice-chancellor Jim Mienczakowski, as quoted by NST

As of the BioValley project in Dengkil, well, a PPBM supreme council member had suggested that the production of ketum and cannabiscan help in reviving it, but thats simply a suggestion. For now, theres been no further news on the BioValley project in Dengkil. When Mahathir returned for his second run as Prime Minister, he didnt say a word about it either.

But all things considered, weve managed to attract major players in the industry into Malaysia. Not just that, Malaysia itself has also been doing pretty well with our own research institutes to boost biotechnology. So it does seem that theres still a pretty bright future for biotechnology in Malaysia.

View post:
In 2003, Dr M had a plan to boost biotech in Msiabut its now a valley of ghosts - CILISOS.MY

SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2020 financial results on Thursday, May 7, 2020, after the close of the market.

Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:30 p.m. PT / 5:30 p.m. ET on May 7, 2020, to discuss first quarter 2020 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

Individuals interested in listening to the conference call may do so by dialing:

US domestic callers: (877) 556-5248Outside US callers: (720) 545-0029Please reference Conference ID: 6873327

A live webcast of the conference call will be available online from the Investor Relations page of the Companys website at Events & Presentations. The link will not be active until 2:15 p.m. PT / 5:15 p.m. ET on May 7, 2020.

After the live webcast, the call will be archived on Fluidigms Investor Relations page at investors.fluidigm.com. In addition, a telephone replay of the teleconference will be available approximately 90 minutes after the end of the call.

The replay dial-in numbers are:

US domestic callers: (855) 859-2056Outside US: (404) 537-3406Please reference Conference ID: 6873327

The telephone replay will be available until May 14.

About Fluidigm Fluidigm (Nasdaq:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOFand microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, theFluidigmlogo, and CyTOF are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.Fluidigmproducts are provided for Research Use Only. Not for use in diagnostic procedures.

Available InformationWe use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases,SECfilings, public conference calls, and webcasts.

Contact:

Agnes LeeVice President, Investor RelationsFluidigm Corporation650 416 7423agnes.lee@fluidigm.com

Read this article:
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results - GlobeNewswire

Puma Biotechnology Inc. [NASDAQ: PBYI] shares went higher by 12.21% from its previous closing of 8.60, now trading at the price of $9.65, also adding 1.05 points. Is PBYI stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 1.09 million contracts. Compared to the average trading volume of PBYI shares, the company saw a far better performance. Moreover, the stock has a 34.74M float and a 20.78% run over in the last seven days. PBYI share price has been hovering between 35.27 and 5.50 lately, and is definitely worthy of attention.

Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Puma Biotechnology Inc. [PBYI], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of 12/30/2019. On average, stock market experts give PBYI an Hold rating. The average 12-month price forecast for this stock is $9.65, with the high estimate being $15.00, the low estimate being $6.00 and the median estimate amounting to $13.50. This is compared to its latest closing price of $8.60.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Puma Biotechnology Inc. [PBYI] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 3.00.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on 05/06/2020.

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology Inc. [PBYI] sitting at -23.30% and its Gross Margin at 86.50%, this companys Net Margin is now -27.80. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -24.14, and its Return on Invested Capital has reached -47.06. Its Return on Equity is -302.70%, and its Return on Assets is -29.10%. These metrics suggest that this Puma Biotechnology Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 688.48. Similarly, its Total Debt to Total Capital is 87.32, while its Total Debt to Total Assets stands at 51.18. Looking toward the future, this publicly-traded companys Long-Term Debt to Equity is 673.45, and its Long-Term Debt to Total Capital is 85.41.

What about valuation? This companys Enterprise Value to EBITDA is -9.35. The Enterprise Value to Sales for this firm is now 1.07, and its Total Debt to Enterprise Value stands at 0.35. Puma Biotechnology Inc. [PBYI] has a Price to Book Ratio of 19.64, a Price to Cash Flow Ratio of 15.16.

Puma Biotechnology Inc. [PBYI] has 38.22M shares outstanding, amounting to a total market cap of 368.82M. Its stock price has been found in the range of 5.50 to 35.27. At its current price, it has moved down by -72.64% from its 52-week high, and it has moved up 75.45% from its 52-week low.

This stocks Beta value is currently 1.21, which indicates that it is 9.49% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 56.30. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

Visit link:
Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis - The Dwinnex

Measuring Apex Biotechnology Corp.s (TSEC:1733) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess 1733s recent performance announced on 31 December 2019 and compare these figures to its historical trend and industry movements.

Check out our latest analysis for Apex Biotechnology

1733s trailing twelve-month earnings (from 31 December 2019) of NT$114m has jumped 20% compared to the previous year.

Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of -28%, indicating the rate at which 1733 is growing has accelerated. Whats enabled this growth? Lets take a look at if it is merely due to industry tailwinds, or if Apex Biotechnology has experienced some company-specific growth.

In terms of returns from investment, Apex Biotechnology has fallen short of achieving a 20% return on equity (ROE), recording 6.7% instead. Furthermore, its return on assets (ROA) of 4.3% is below the TW Medical Equipment industry of 6.2%, indicating Apex Biotechnologys are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for Apex Biotechnologys debt level, has declined over the past 3 years from 12% to 9.3%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 21% to 29% over the past 5 years.

Apex Biotechnologys track record can be a valuable insight into its earnings performance, but it certainly doesnt tell the whole story. Recent positive growth isnt always indicative of a continued optimistic outlook. There may be factors that are impacting the industry as a whole, thus the high industry growth rate over the same time period. You should continue to research Apex Biotechnology to get a better picture of the stock by looking at:

NB: Figures in this article are calculated using data from the trailing twelve months from 31 December 2019. This may not be consistent with full year annual report figures.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

View post:
Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? - Simply Wall St

Every three months, David Martin, a quadriplegic, returns to a small clinic here in the Russian capital for therapy he cannot legally get back home in Kalamazoo, Mich.: injections of stem cells taken from his own body, at a cost of $12,000 per visit.

MOSCOW Every three months, David Martin, a quadriplegic, returns to a small clinic here in the Russian capital for therapy he cannot legally get back home in Kalamazoo, Mich.: injections of stem cells taken from his own body, at a cost of $12,000 per visit.

Martins U.S. doctors have tried to dissuade him from believing any improvement in his condition could be the byproduct of stem-cell treatments, a therapy not yet approved in the United States. No scientific evidence has ever shown that such treatments can repair human spinal-cord injuries, experts say.

Yet Martin notices glints of progress a twinge of sensation in one of his curled, still hands, a faraway feel of something cold on his skin. He attributes it to the stem-cell treatments he has been getting in Moscow.

Its definitely unfortunate that the U.S. isnt doing this, said Martin, 36, paralyzed since a car accident in 2006. Its not an inexpensive venture, and its not easy on the body to have to travel this distance.

Martin is just one of a growing number of Americans and Europeans turning to Russia, China and other countries where the stem-cell industry operates unfettered and largely unregulated.

NeuroVita, the clinic Martin has been visiting since 2007, attracts paraplegics and quadriplegics from around the world and maintains a waiting list for overflow clientele. Elsewhere in the capital, chic beauty clinics rely on stem-cell therapy to beckon Moscows moneyed elite, pitching the treatments as a surefire answer to wrinkles and stretch marks.

What troubles critics is the rush in some countries to offer stem-cell therapy on the health-care market, the absence of governmental oversight associated with stem-cell treatments in those countries, and the lack of any proof that the treatments actually work. If patients feel improvement, experts say, its likely a placebo effect or the result of their bodys own healing mechanisms.

NeuroVita relies on adult stem cells taken from the patients own bone marrow, a type of stem cell widely regarded as having far less therapeutic potential than embryonic stem cells stem cells derived from human embryos.

About making money

While adult stem cells may be useful in treating cancer or brittle-bone disease, most experts think its impossible to turn blood-derived adult stem cells into nerve cells, and that anyone offering such treatments is not relying on peer-reviewed science.

I dont think theres much science to it, said Vladimir Smirnov, director of the Moscow Institute of Experimental Cardiology, a licensed Russian stem-cell researcher and a leading critic of clinics that sell stem-cell injections. Its all about making money.

The wonder of stem cells lies in their ability to reproduce and differentiate into whatever variety of tissue the body requires. Adult cells do not reproduce, but stem cells divide freely. Stem cells also tend to seek out damaged tissue, making them catalysts for restoration. In recent years, scientists have been encouraged by research that suggests stem-cell therapy could one day be applied to a wide array of disorders and injuries.

A recent study involving rats with Parkinsons disease showed that embryonic stem cells genetically altered to yield dopamine-producing neurons could be transplanted into the rats brains and improve motor function. Other studies have shown that adult stem cells injected into mice with damaged hearts can repopulate heart tissue with new heart-muscle cells.

Doctors have been relying for four decades on bone-marrow transplants that use adult stem-cell technology to treat cancers such as leukemia and lymphoma.

But the U.S. Food and Drug Administration (FDA) has yet to approve embryonic or adult stem-cell injections to treat other disorders. The FDA allows stem-cell clinical trials involving humans, but the research is carefully controlled and usually involves a small number of patients.

Elsewhere in the world, however, regulations governing stem-cell therapy are lax and usually poorly enforced.

In Russia, the Federal Health Inspection Service must approve a clinics use of stem-cell therapy. Several years ago, Russian authorities shut down more than 30 medical institutions illegally carrying out stem-cell treatments, but numerous clinics continue to sell the injections under the radar of regulators.

Clinical trials allowed

A Moscow clinic called Beauty Plaza has the governments permission to carry out adult stem-cell injections within the framework of clinical trials. The stem cells are taken from the patients fatty tissue. Usually, subjects of clinical trials do not pay for their treatments, but Beauty Plaza clients have to pay for theirs, says the clinics director, Alexander Teplyashin.

We can eradicate atherosclerosis symptoms, and we can cure diabetes Type 2, Teplyashin said confidently during an interview at his clinic. After the treatments, patients stop getting the flu. They become more energetic, more active.

According to its Web site, NeuroVita has governmental approval to offer adult stem-cell therapy to neurological patients. The clinics director, Andrei Bryukhovetsky, said NeuroVita has used stem-cell treatments on 200 patients since 2002, 70 percent of them foreign citizens and at least 30 patients from the United States.

Bryukhovetsky touts results that most experts would label as doubtful: A young man from Siberia paralyzed from the neck down now eats on his own, drinks tea, all within a year. For another patient with a spinal-cord injury in his neck, one injection was enough. After one day he began writing, Bryukhovetsky said.

How can we explain it? I dont know, Bryukhovetsky said. But it works.

The trouble with such anecdotal evidence, said Evan Snyder, a U.S. expert on stem-cell research, is that it lacks credibility. And the best environment to ensure that credibility, Snyder said, is a proper, well-controlled clinical trial.

Anecdotal evidence doesnt mean anything to me, said Snyder, a stem-cell researcher at the Burnham Institute in La Jolla, Calif. Im happy for the patient if he feels better. But one has to be cautious about what to attribute that improvement to.

Stem-cell treatments arent without risk, Snyder adds.

It could be a situation where the stem cells go to the wrong place in the body, or they are the wrong type of cells for a given region, he said. They could turn into cancer themselves, or cause neighboring cells to become cancerous.

It remains unclear when stem-cell technology will be ready for broader application in U.S. health care. Patients like Martin say they dont want to wait.

Patient sees progress

On a recent afternoon in a physical-therapy room at NeuroVita, Martin demonstrated what he believed was progress attributable to the stem-cell injections he received in his spine. He winced slightly as his hands, fastened to weight machine handles with leather straps, pulled back to lift 55 pounds. Before the treatments, he could lift just 2 pounds, he said.

Ive come a long way, Martin said. Seems like every time I come back from Russia, Ive gone up 5 or 10 pounds.

Martin, manager of an automotive component plant before the accident, spent $33,000 on an initial visit, for an overall cost of about $81,000 on five visits to NeuroVita since June 2007.

He believes hell need one more year of treatments.

If someone has the wherewithal to do something like that and it improves their psychological well-being, I wouldnt prevent them from doing it, said, Snyder the stem-cell researcher, as long as they recognized that the likelihood for improvement is minimal.

Follow this link:
Stem-cell therapy in Moscow attracting patients from West ...

Futuristic Reports, The growth and development of Global Stem Cell Umbilical Cord Blood Market Report 2020 by Players, Regions, Type, and Application, forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Stem Cell Umbilical Cord Blood Market analysis delivers important insights and provides a competitive and useful advantage to the pursuers. Stem Cell Umbilical Cord Blood processes, economic growth is analyzed as well. The data chart is also backed up by using statistical tools.

Simultaneously, we classify different Stem Cell Umbilical Cord Blood markets based on their definitions. Downstream consumers and upstream materials scrutiny are also carried out. Each segment includes an in-depth explanation of the factors that are useful to drive and restrain it.

Key Players Mentioned in the study are Cell Care, Cells for Life, Cryolife, Cryo-Cell, CBR (Cord Blood Registry), Stemlife, CELLTREE(CELLTREE), StemOne Biologicals, Healthbanks Biotech, Stemcyte Inc, Smart Cells, ViaCord, LifeCell, Cryosite, Cordlife

For Better Understanding, Download FREE Sample Copy of Stem Cell Umbilical Cord Blood Market Report @ https://www.futuristicreports.com/request-sample/39381

Key Issues Addressed by Stem Cell Umbilical Cord Blood Market: It is very significant to have Stem Cell Umbilical Cord Blood segmentation analysis to figure out the essential factors of growth and development of the market in a particular sector. The Stem Cell Umbilical Cord Blood report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for players to focus and highlight on.

Businesses Segmentation of Stem Cell Umbilical Cord Blood Market:

On the basis on the applications, this report focuses on the status and Stem Cell Umbilical Cord Blood outlook for major applications/end users, sales volume, and growth rate for each application, including-

Blood Disorders Cancers Immune Disorders Metabolic Disorders Others

On the basis of types/products, this Stem Cell Umbilical Cord Blood report displays the revenue (Million USD), product price, market share, and growth rate of each type, split into-

Allogeneic stem cell umbilical cord blood Autologous stem cell cord blood

Grab Best Discount on Stem Cell Umbilical Cord Blood Market Research Report [Single User | Multi User | Corporate Users] @ https://www.futuristicreports.com/check-discount/39381

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

OR

You just drop an Email to: [emailprotected] us if you are looking for any Economical shift towards the New Normal on any Country or Industry Verticals.

Stem Cell Umbilical Cord Blood Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Stem Cell Umbilical Cord Blood Insights that Study is going to provide:

Gain perceptive study of this current Stem Cell Umbilical Cord Blood sector and also possess a comprehension of the industry; Describe the Stem Cell Umbilical Cord Blood advancements, key issues, and methods to moderate the advancement threats; Competitors In this chapter, leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. A separate chapter on Stem Cell Umbilical Cord Blood market structure to gain insights on Leaders confrontational towards market [Merger and Acquisition / Recent Investment and Key Developments] Patent Analysis** Number of patents filed in recent years.

Table of Content:

Global Stem Cell Umbilical Cord Blood Market Size, Status and Forecast 20261. Market Introduction and Market Overview2. Industry Chain Analysis3. Stem Cell Umbilical Cord Blood Market, by Type4. Stem Cell Umbilical Cord Blood Market, by Application5. Production, Value ($) by Regions6. Production, Consumption, Export, Import by Regions (2016-2020)7. Market Status and SWOT Analysis by Regions (Sales Point)8. Competitive Landscape9. Analysis and Forecast by Type and Application10. Channel Analysis11. New Project Feasibility Analysis12. Market Forecast 2020-202613. Conclusion

Enquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/39381

For More Information Kindly Contact:

Futuristic ReportsTel: +1-408-520-9037Media Release: https://www.futuristicreports.com/press-releases

Follow us on Blogger @ https://futuristicreports.blogspot.com/

See original here:
Stem Cell Umbilical Cord Blood Market 2020 Share Insights and Dynamics | Cells for Life, Cryolife, Cryo-Cell Cole Reports - Cole of Duty

In 2016, astronomers spotted the brightest supernova ever observed. They watched as the supernova, named SN2016aps, continued to emit radiation for more than 1,000 days. Today, in a paper published in Nature, they describe how this extremely energetic supernova could help them understand the universes evolution and the formation of the most massive stars.

SN2016aps flared so brightly that it outshone its own galaxy, and over its long span, it emitted more light than any supernova on record, Matt Nicholl, the studys first author from the University of Birmingham in the United Kingdom, told Gizmodo. At five to 10 times the mass of a typical supernova, it was one of the largest stars ever seen to explode. The total mass of the object and the material it ejected before exploding could have been 50 to 100 times the mass of the Sun, Gizmodo notes.

SN2016aps likely occurred around 10 billion years after the Big Bang. Now, with data from this supernova and more powerful telescopes like the James Webb Space Telescope, the researchers hope to find similar events even further back in the universes history, when they may have been more common.

See more here:
Astronomers observe the brightest supernova on record - Yahoo Lifestyle

Even after death, COVID-19 could be contagious, a new report finds.

A forensic practitioner working in Bangkok, Thailand, most likely caught the virus from a deceased patient, according to the report, which was posted online April 11 as a preprint for the Journal of Forensic and Legal Medicine.

The forensic practitioner later died of the virus, marking the first case on record of a "COVID-19 infection and death among medical personnel in a forensic medicine unit," the researchers wrote in the report.

Related: Latest COVID-19 news and US case counts

At the time the report was written on March 19, just 272 people in Thailand including the forensic practitioner and a nurse assistant had tested positive for the new coronavirus. Most of these cases were imported, meaning they weren't from community spread, the researchers wrote. So, it's unlikely that the forensic practitioner caught the new coronavirus outside of work or even from a patient at the hospital, the researchers wrote.

"There is [a] low chance of forensic medicine professionals coming into contact with infected patients, but they can have contact with biological samples and corpses," the researchers wrote in the report.

It's not surprising that the body of a recently deceased COVID-19 patient might be contagious, said Dr. Otto Yang, a professor in the Department of Medicine and the Department of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at UCLA.

"Absolutely, a dead body would be contagious at least for hours if not days," Yang told Live Science in an email. "The virus will still be in respiratory secretions, and potentially still reproducing in cells that haven't yet died in the lungs."

COVID-19's longevity in the body can be problematic for people in the funerary industry. For instance, following reports that temples in Thailand were refusing to perform funeral services of COVID-19 victims, the head of Thailand's Department of Medical Services incorrectly announced on March 25 that the disease was not contagious in bodies after death, according to Buzzfeed News.

It's unclear, however, just how long the virus remains infectious in a dead body.

In light of this finding, forensic scientists should take a number of precautions while examining the remains of COVID-19 patients, the researchers said. For instance, forensic professionals should wear protective gear, including a protective suit, gloves, goggles, a cap and a mask, they wrote.

"The disinfection procedure used in operation rooms might be applied in pathology/forensic units too," they added.

Usually, pathogens that kill people don't survive long enough to spread to others after the person's death, according to the World Health Organization (WHO). "Human remains only pose a substantial risk to health in a few special cases, such as deaths from cholera or haemorrhagic fevers," such as Ebola, the WHO said.

Other illnesses that are contagious in human remains include tuberculosis, bloodborne viruses (such as hepatitis B and C and HIV) and gastrointestinal infections (including E. coli, hepatitis A, Salmonella infection and typhoid fever), according to the WHO.

Originally published on Live Science.

Read the original here:
The bodies of COVID-19 victims may be contagious, coroner's case reveals - Livescience.com

A livestock farmer is firstly a veld and pasture farmer. It is vital that the animals nutritional requirements are met, especially during breeding and when the cows are raising calves.

Moreover, the cattle should be fully fed in a relatively short period of grazing. This implies that the farms fodder flow must be sufficient throughout the year.

Arguably the most crucial aspect of grazing management after establishing the correct stocking rate is to ensure that a portion of the veld and pasture is given a periodic rest period comprising a full growing season.

The foremost economic factor of a cattle farming enterprise is fertility. It is five times more important than growth performance, which in turn is five times more important than carcass quality. Obviously, it is better to have a poorly performing calf than no calf at all.

Management & geneticsFertility has both a management and a genetic component. The management component includes all those aspects, such as feeding correctly and maintaining animal health, that are your sole responsibility as a farmer.

It also includes maintaining strict breeding seasons in order to establish which animals are not reproducing. Breeding seasons make it far easier for you to use a veterinarian to determine which cows have failed to conceive.

Good management enables animals to produce and reproduce optimally. The genetic component of fertility is limited to 10% heritability. However, it is highly repeatable, so make sure to identify the cow families that calve every year.

Just to be clear: heritability is a reflection of the degree to which offspring performance is a reflection of the performance of their parents.

Repeatability is a measure of the strength of the relationship between repeated records. As a producer, knowing the repeatability of a trait can help you make culling decisions. You can also use repeatability as a measurement to predict early on how productive a cow will be over her lifetime in terms of milk production and calf weaning.

Breeding valuesSelect for genetic traits that are positively correlated with fertility, such as scrotal size and mature body mass, and consider the fertility index itself, such as days to calving. These are expressed as estimated breeding values (EBVs).

Remember, however, that if the animals feed and other requirements are not met, you cannot correct for this by selecting for higher fertility on a genetic level.

Scrotal size in bulls plays a major role in determining the fertility of the female offspring. It is true that bigger is better, but only up to a point. Look at the scrotal size or scrotal circumference EBVs of the bulls you buy, and physically examine scrotal development. Two equally well-developed testes with good epididymis development are very important.

Another key trait is mature weight, which should always be kept in check. The EBV for mature weight should ideally be around breed average. Your aim should be to breed cows that calve easily and produce fast-growing calves, but you dont want breeding stock that are too large by the time they wean their first calf, because big cattle have high maintenance requirements. Moreover, animals that are heavy at maturity are often less productive.

The days-to-calving fertility index identifies bulls and cows that carry the genes producing fertile progeny. Animals that take less time to calve from the initial mating date have a better days-to-calving index and are thus more fertile.

This index also plays a large part in the overall economic indices for certain systems, such as a self-replacing feedlot.

Bull selectionA bull has a 50% genetic influence on a herd of females that he gets into calf. Its therefore crucial to buy and use bulls with the correct fertility and growth attributes. The old adage, A good bull is half your herd and a bad bull is your whole herd, holds true.

Be sure to maintain the correct bull-to-cow ratio and to test bulls regularly for fertility and sexually transmitted diseases.

As a general guideline, a two-year-old bull should be able to cope with 20 females in a two- to three-month breeding season. At three years old, a bull should service 30 females within this time frame, and by four years, he should be able to breed with 40 females.

Early calvers are generally the more fertile animals. The shorter you make your calving season, the more fertile your herd will become. Ideally, 60% of your females should calve in the first 30 days of the season. By selling your late calvers, you also in effect shorten your breeding season.

CrossbreedingHybrid vigour increases fertility, growth and longevity, so it pays to crossbreed. But this must be carried out in a structured way, and good management is essential. A normal crisscrossing system or a three-way cross system can be followed.

It is also very important to choose a breed or type of cattle that is suited to your environment and farming system.

Under more extensive conditions (in large parts of the country), breeds with a certain mix of Bos taurus (for production) and B. indicus (for hardiness and adaptability) demonstrate greater fertililty. Under more intensive and higher-rainfall systems, B. taurus-type breeds do better.

Under extremely arid and hot conditions where the stocking rate is very low, indigenous B. indicus-type cattle and Brahmans fare best.

Email Llewellyn Angus at [emailprotected].

More here:
The fundamentalsof fertility in beef cattle - Farmer's Weekly

Editors note: Phil Gianficaro is a native of Pittston as was his mom, Josephine Gianficaro, who died Wednesday, April 8, of COVID-19. She was 88.

***

Our moms lifetime of generosity, not her death due to COVID-19 last week, will endure as her legacy.

She was where we could not be. A stranger with compassion in her heart and wings on her back. A palliative care nurse doing for my mom in her final hours that which COVID-19 forbade us from doing.

The nurse sat at Moms bedside in the dark and quiet of the quarantine hospital room as the stroke of midnight and her final moments approached. Head to toe in protective garb, she gently wound rosary beads in Moms fingers, stroked her cheek, held her hand, offered prayers. Administering Gods providence. A stranger doing for Mom what the virus wouldnt allow us to do: comfort her at the end.

The nurses name is Mary.

Fitting.

Coronavirus took my mother from us last week. Hers was the cruelest of goodbyes. Isolated. Unconscious. Alone, except for a nurse dispensing endless helpings of love we could not. Saying thank you from the bottom of our hearts comes up woefully short.

A week earlier, cancer was losing its battle against my mom. After three months and four cycles of chemotherapy, tumors caused by diffuse, large B-cell lymphoma were shrinking. Mom, at 88, was punching like a champ, whipping cancers tail. Only two chemotherapy cycles remained before she could begin thinking about returning to her kitchen to bake and deliver cakes and cookies for family and friends. While everyone thanked her, her gift was in the giving. A lesson for us all.

Cancer, fighting out of its weight class, looked at the scorecard with swollen eyes from unsteady knees about to surrender. Trailed late in the fight. Reinforcements were summoned. Enter coronavirus. A week later, Moms fight was over.

Sometimes there just arent enough punches.

While our hearts are breaking, anger toward the Lord does not rule my heart. When the end came, I closed my eyes and said a prayer, thanking God not only for blessing us with a wonderful mother for 60 years, but also for calling her home before more intense pain and suffering took hold.

While we wait for a shuttered world to reopen, to return to some degree of normal, our grief continues. Moms funeral arrangements, as are those of so many loved ones across the nation, are on hold. So, too, is what we as a family need most: a gathering to hug and cry and laugh and reminisce and celebrate the most loving, caring and magnificent person I ever knew. So we wait.

Mom was an umbrella when it rained, a scarf to blunt the chill, a smile to chase the sadness. A well of humanity that never ran dry. She checked all of Jesus boxes: Caring. Generous. Friendly. Faithful. Nurturing. Selfless. Loving. In the alphabet of concern, Mom was letter Z. Back of the line. Her choice. The less fortunate needed love and attention and comfort more. You go ahead, shed say. I can wait. Ill make do.

Whats Mrs. G. baking today? our friends would ask when my younger brother and I were kids. They loved sitting around Moms kitchen table, eagerly waiting for the oven door to open. Your kitchen always smells so good, Mrs. G., they would say. Pies. Cakes. Cookies. Comforting aromas from the oven, my friends assumed. They were wrong. What made them feel so good came not from her stove, but from her heart.

The stories are endless. Leaving a Thermos of coffee and a bag of baked goods on the front porch for trash collectors every week during the harsh winter months. Baking a Thanksgiving dinner for a poor neighbor family whose husband and father had lost his job a few weeks earlier. Several years ago, she phoned a surgeon decades after his medical magic ensured her sons a better life, to thank him again. The docs wife called back the next day. Hes beaming! she told Mom. You made his day! The well never ran dry.

As I turn an ear to heaven, I can hear the conversation:

St. Peter!

Yes, Jesus.

Your pants are getting a little tight around the waist, dont you think?

Yeah, Lord, um, Josie has been up here with us for a few days now. The cheesecakes. The Italian cookies. The cannolis. The rigatoni and meatballs in homemade sauce. The stuffed peppers. I cant resist. It all just smells so good.

Any cheesecake left?

Um, dont think so, Lord.

Then a sweet voice from heavens kitchen to Jesus ears:

How big a slice do you want? I have more.

With Mom, there was always more.

Phil Gianficaro

Columnist Phil Gianficaro can be reached at 215-345-3078, pgianficaro@theintell.com, and @philgianficaro on Twitter.

Go here to read the rest:
Gianficaro: COVID-19 took my mom, but her legacy lives on - The Sunday Dispatch

David Johnson believes people are indulging in misconceptions about his longevity and durability.

The 6-1, 224-pound running back earned first-team All-Pro in 2016, his second season as a pro with the Arizona Cardinals. After dislocating his wrist the following year and missing the balance of the season after Week 1, Johnson disappeared from the national spotlight, much like the Cardinals who went through two coaching changes in that span.

Even though Johnson started all 16 games in 2018 and almost tallied 1,000 rushing yards, there are doubts about his durability and longevity.

I think that really is a big misconception, especially in this league, Johnson told the Houston media on a conference call. Its football. Guys get nicked up, get injuries all the time, so you cant really predict whats going to happen. I know that Im going to do everything that I can to be ready and keep my body as healthy as possible.

Johnson produced 2,101 scrimmage yards and 16 total touchdowns in his 29 games following his wrist dislocation in 2017.

I think that the biggest thing that Im going to really focus on is doing overtime as far as keeping my body healthy, said Johnson. Maybe doing the cold tub a little longer, doing treatment a little longer, even if I dont need to. Maybe I got a little bruise, just making sure I make sure thats as healthy as possible before I even go step on the practice field or in a game. I think thats the biggest thing.

Johnsons focus, whether doubts about his availability and health existed or not, is to get back into the shape that led to his meritorious 2016 season when he led the league with 2,118 scrimmage yards and 20 total touchdowns. In order to get back to that 2016 form, the former 2015 third-round pick from Northern Iowa is hearkening back to his rookie seasons preparations.

Just going back to my rookie year of doing everything that I can to make sure that my body is healthy and starting a clean slate for sure with a new team, Johnson said.

If the Texans can get a revitalized Johnson, they will have a formidable starter in the backfield behind two-time Pro Bowl quarterback Deshaun Watson.

More here:
Texans RB David Johnson corrects the record on his longevity and durability - Texans Wire

OMAHA, (Neb.) Missy Henry from Edge Body Boot Camp says one of the most important parts of your body to work out is your back. Our cars in front of us the remote is in front of us. We're sitting at a computer. Everything in our daily life pulls us forward anyway so that back needs to be strengthened just for posture health for shoulder longevity a lot of things, said Henry.

In this weeks Move It Monday, were working this muscle group with a unique line-up. Instead of working out for 20 minutes, your goal is complete a certain amount of reps. Youll start by doing ten reps of bent over rows, straight-arm pull-aparts, and bicep curls. From there youll do mountain climbers, but instead of doing 10, youll add a zero to it and do 100. Each round youll go down by one. So we're doing 10 reps of everything. 9 reps of everything. Eight reps of everything and so your last round is going to be one, said Henry.

THE WORKOUT: After warming up complete the following rounds. When you are done, spend 5-10 cooling down.

Round 1:

10 bent over rows, straight-arm pull-aparts, and bicep curls.

100 mountain climbers (50 on each foot).

Round 2:

9 bent over rows, straight-arm pull-aparts, and bicep curls.

90 mountain climbers (45 on each foot).

Round 3:

8 bent over rows, straight-arm pull-aparts, and bicep curls.

80 mountain climbers (40 on each foot).

Round 4:

7 bent over rows, straight-arm pull-aparts, and bicep curls.

70 mountain climbers (35 on each foot).

Round 5:

6 bent over rows, straight-arm pull-aparts, and bicep curls.

60 mountain climbers (30 on each foot).

Round 6:

5 bent over rows, straight-arm pull-aparts, and bicep curls.

50 mountain climbers (25 on each foot).

Round 7:

4 bent over rows, straight-arm pull-aparts, and bicep curls.

40 mountain climbers (20 on each foot).

Round 8

3 bent over rows, straight-arm pull-aparts, and bicep curls.

30 mountain climbers (15 on each foot).

Round 9

2 bent over rows, straight-arm pull-aparts, and bicep curls.

20 mountain climbers (10 on each foot).

Round 10

1 bent over rows, straight-arm pull-aparts, and bicep curls.

10 mountain climbers (5 on each foot).

Read more from the original source:
MOVE IT MONDAY: Back Workout - KMTV - 3 News Now

Yesterday, Apple announced the new $399 iPhone SE. The TL;DR appears to be really simple: the iPhone 8s body, the iPhone 11s processor, and the iPhone XRs camera system with a few new capabilities. Ill obviously wait to review this phone to tell you if its any good, but assuming Apple lives up to its usual standards I can tell you something right away:

At $399, the second-generation iPhone SE is a shockingly good value.

The most important thing to know about the SEs value proposition is simply that it has the A13 Bionic processor, which is bar-none the fastest processor you can get on any smartphone at any price, full stop. You could spend $1,449 on a fully maxed-out iPhone 11 Pro Max and it wouldnt be faster than the iPhone SE. You could spend $1599.99 on a maxed-out Samsung Galaxy S20 Ultra 5G and it would be theoretically slower (with the exception of 5G downloads).

This isnt just a matter of processor megahertz per buck, its a matter of the longevity of the phone itself. More than any other phone company, Apple supports its phones for a very long time. Since this iPhone SE has the most modern processor available, its quite likely that it will receive software updates for many years to come.

Hell, Apple even did the right thing with storage: offering a humane 64GB at the base level and making the 128GB model only $50 more.

Over the course of 2019, we marveled at the level of quality you could get in a long series of relatively inexpensive Android phones. Thats still true today, but those phones will receive three years of updates from Google at most. And as my colleague Chris Welch will argue later today, the iPhone SE sets a bar that the upcoming Google Pixel 4A will have an incredibly difficult time clearing.

Again, well need to review the new iPhone SE and the Pixel 4A to know whether one of them has an advantage with any particular feature (like the camera). So no final judgements here. But I just need to point out that for most of 2018 and 2019, every Android maker has had a bit of a green field to play in: phones that cost less than $500.

Google, Asus, Samsung, and many others did good work in that green field, but now theres real competition from Apple.

On Tuesday in this newsletter, I had half a thought about these low-cost phones. Forgive me for quoting myself:

Increasingly, I find that flagship phones are mainly about luxuries instead of tangible benefits to most people. Those luxuries include screen quality, 5G, wireless charging, face unlock, speed, overall build quality, camera quality, and a smattering of other things.

Will the iPhone SE match the iPhone 11 or 11 Pro on most of those metrics? Nope. But when I wrote that I hadnt imagined that Apple would use its newest chip. The inclusion of the A13 Bionic means the SE will match the most luxurious phone on speed and on longevity.

I know Ive now brought up software updates twice now, but its super important. $399 spent on this iPhone SE means its less likely youll be forced to spend another $399 next year or the year after.

There are several things to be bummed about with the iPhone SE 2 starting with the fact that Apple calls it the second-generation iPhone SE, which is a bad name. Eventually well settle on what to call it, but until then prepare for iPhone SE, second-generation iPhone SE, iPhone SE 2, iPhone SE (2020), the new iPhone SE, and probably something I cant imagine right now. Ugh.

I kid, thats not really a real problem. Neither is the claim that this is just a parts bin phone. Yes, Apple is using a lot of parts that have been bouncing around its product lines for years. But, and I want you to really feel this: who cares? It doesnt matter how old the parts are if theyre good.

No, there are real issues we know about already just from the basics. For example, this form factor the same as the iPhone 6 isnt especially inspiring. I hate the size of the bezels. It seems like a petty complaint, but reducing them really does change your experience. You get more screen in a smaller body. Plus, its something most Android phones accomplished by putting a fingerprint sensor on the back or under the screen.

Speaking of size, this iPhone SE is larger than the last iPhone SE, which means that even small phones are big now, as Dan Seifert observed yesterday. Finding a truly good, truly small smartphone is nigh impossible right now.

And though I know many people will tell me to just get over it already, the fact that this low-cost iPhone lacks a traditional headphone jack is a bit of a bummer. Other low-cost Android phones explicitly include them. Bluetooth headphones arent just another thing to charge, theyre another thing to buy and another thing that could break.

Apple has a reputation for overcharging for hardware. Its become a point of contention in the flamewars between Apple, Windows, and Android stans. My take is that sometimes Apple is guilty and sometimes its not. The new MacBook Air is a great value. Selling Mac Pro wheels for $699 and literal metal posts for $299 is so incredibly hilarious that even pointing out that its become self-parody feels so obvious its embarrassing.

On that spectrum, the new iPhone SE (or whatever we decide to call it) is not just a good value for Apple. Its one of the very best values Ive seen in the smartphone market in years. In theory, at least: now we just have to test it and see if it lives up to its spec sheet.

Apples second-gen iPhone SE is here: all the news and details. Heres a story stream of all of our iPhone SE 2 coverage.

The iPhone SE 2s camera setup is going to lean on Apples software. Jon Porter on how Apples advances in image processing are going to be vital to this phones success.

Apples new iPhone SE doesnt come with custom U1 locator chip. Its not in the new iPad Pro with LiDAR either, where you would think it would make sense as the iPad Pro is practically designed for AR and AR development. I dont know whats up with the U1 chip (or AirTags), but increasingly it feels like something is weird about the whole thing.

Apples new Magic Keyboard for the iPad Pro goes up for preorder, ships next week. Heres something unexpected! Long ago I promised to share my thoughts on the trackpad support in iPadOS but havent really finished that thought yet. When I review this, I will.

Dells new XPS 13 is everything a Windows laptop should be. Monica Chin on what is going to be a contender for best Windows laptop of 2020, if not best laptop full stop:

The XPS 13 speaks for itself. This isnt a laptop thats trying to push boundaries or rewrite the rules; its just giving users what they want. I would take a better webcam, I would take better cooling, I would take a USB-A, and I would take a slightly more color-accurate screen. But none of those are glaring flaws because they arent big impediments to the user experience. And in the areas that matter most build, display, keyboard, touchpad, battery life, performance the XPS 13 doesnt just check all the boxes. It blows the boxes off the page.

The TurboGrafx-16 Mini is a great plug-and-play console that doubles as a history lesson. Andrew Webster reviews:

The TurboGrafx-16 Mini fills a different niche. For many people, it wont be a chance to revisit classic games from their youth, but instead an opportunity to discover a period of retro gaming they likely missed the first time.

Google and Apples COVID-19 tracking system cant save lives all on its own. Nicole Wetsman on what the rollout of this system should actually look like. Its clearly built to be part of a larger system of testing and communal action. If the latter doesnt come, the former wont be of use (and could actually be a detriment). As ever, we need more testing, more PPE, and consistent guidance from political leaders. All three are in short supply.

How GM and Ford switched out pickup trucks for breathing machines. Sean OKane explains how ventilators are much more complicated than you might realize.

Automakers are well-suited for these partnerships for a few reasons, according to Adrian Price, the global vehicle engineering director at Ford whos overseeing the companys ventilator effort. Not only do these companies already work with components that are similar to the ones found in ventilators, but cars are highly complex products that require a unique amount of knowledge, planning, coordination, and logistics to build.

Russia conducts another test of its missile system to take out satellites. Loren Grush explains many of the reasons why these tests are not a good idea.

ASAT tests are also widely condemned by many in the space community, as these demonstrations typically create hundreds to thousands of pieces of debris that can last for months, and even years, in orbit. Because these tests are high speed and high impact, the resulting debris can spread far and wide. Those pieces then pose a threat to other functioning spacecraft. A fast-moving piece of junk can render an operational satellite inoperable if they hit head on.

What Payment Status Not Available on the IRS coronavirus aid site means. Bad error messages are terrible in the best situations. Here, its awful, and Adi Robertson tells us exactly why this dark pattern is a huge problem.

How a new book about Instagram changes our understanding of the founders departure. Casey Newton has a review and some insight on Sarah Friers new book: No Filter: The Inside Story of Instagram. Ive fallen out of my reading habit since I started working from home so much, but I am excited enough about this book that I think itll push me back into it again.

Ecobees new security camera doubles as an Alexa speaker. Dan Seifert looks at Ecobees new product line, which you can turn into an inexpensive home security system.

The device is actually just one piece of a new home security platform, which the company calls Haven. In addition to the new SmartCamera, Ecobee is also introducing SmartSensor for doors and windows, a combination entrance and motion sensor thats not unlike Googles Nest Detect.

See the original post here:
The new iPhone SE is a shockingly good value - The Verge

Who is Michael Jordan's real competition for the greatest NBA player of all time?

MJ's last championship run with the Chicago Bulls is captured in "The Last Dance," a 10-part documentary series debuting on ESPN on Sunday (9 p.m. ET). That sixth and final title helped Jordan earn a strong claim for GOAT status, with the Hall of Famer finishing No. 1 in ESPN's all-time NBArank in 2016.

But do legends such as Wilt Chamberlain, Bill Russell, Magic Johnson and Kareem Abdul-Jabbar have a stronger case than Jordan? What about LeBron James? And what qualities make one player the GOAT?

Heading into the series premiere, our NBA experts answer the biggest questions about the best basketball players ever.

MORE: Remembering the greatness of Michael Jordan and the Bulls dynasty

Bobby Marks: I've got 10 on my list for discussion: Wilt Chamberlain, Oscar Robertson, Michael Jordan, Magic Johnson, Larry Bird, Tim Duncan, Karl Malone, Kobe Bryant, Shaquille O'Neal and LeBron James. If you ask me the same question in 10 years, that list might also include one current and one former Golden State Warrior: Stephen Curry and Kevin Durant.

Jackie MacMullan: For the purposes of this discussion, I have 11 players who need no introduction: Jordan, Russell, LeBron, Magic, Wilt, Oscar, Kareem, Shaq, Bird, Kobe and Jerry West.

Marc Spears: This conversation should definitely be a short one. The only former players I have are Magic, MJ, Wilt and Kareem, though I do go back-and-forth about Bird, Robertson, Hakeem Olajuwon, Duncan, Kobe and Shaq. What keeps Russell off that list for me is that he was not a dominant force on the offensive end. The only current player who gets GOAT consideration is LeBron, but I do believe Kevin Durant and Giannis Antetokounmpo have potential to join that discussion.

Kevin Arnovitz: Poring over the list of greats, I can assemble a case for only five players -- Abdul-Jabbar, Chamberlain, James, Jordan and Russell. This is a particularly difficult debate because digging into comprehensive statistics and footage from NBA history is damn near impossible. How many of even today's most rabid NBA fans under the age of 60 can say that they've watched more than a glimpse of Russell? How many of even the most advanced analysts can say that they have a real pulse on how to quantify Chamberlain's career based on the numbers available from his era?

1 Related

Kevin Pelton: I think four players have a legitimate case depending how you define what it means to be greatest: Jordan, James, Chamberlain and Russell. This seems unfair to Abdul-Jabbar, who plausibly had the best career of anyone before Jordan and LeBron, but of this group, he doesn't seem to dominate any single criteria except longevity.

Arnovitz: The GOAT should achieve sustained individual dominance over the long span of his career, coupled with team success. He should be among the very, very best for a very, very long time. He should also leave an indelible imprint on the game -- how we imagine basketball as an ideal, how we think of stardom, how those who come later adopt or appropriate his game.

MacMullan: There are great all-time players who have never won a championship, but everyone on my list has snagged at least one. West would have won multiple rings had he not annually run into the Russell/Bob Cousy/Sam Jones Celtics buzz saw. Game winners in clutch playoff situations also carry weight with me.

Spears: Winning multiple championships is certainly important to being a GOAT. So is leadership and the ability to make others better. You should not only succeed at multiple positions, but also on both ends of the floor. Handling defeat with grace is important. Having big moments in the biggest of games stands out. Enjoying the game and having a star personality is important too.

Pelton: To me, the question goes like this: If we put all players' careers in a draft, considering injuries and retirements, who would give the team you drafted the most championships? This means considering individual performance only to the extent that it drives championships, but also considering how the championships a player actually won are dependent on situation, teammates, coaching and good or bad fortune. I find it also appropriately balances the choice between peak value and longevity.

Marks: The same three characteristics that should be used when determining the MVP: wins, longevity and the impact that player had on his team.

2:03

Stephen A. Smith isn't ruling out the possibility of LeBron James catching up to Michael Jordan as a global brand.

MacMullan: Michael Jordan remains the greatest player of all time in my mind. His six championships were won in two different phases of his career with rotating supporting casts. MJ was a dominant offensive player who hit countless iconic game winners, but he was equally frightening on the defensive end. And he was a killer -- the most ruthless competition the game has ever seen.

The 10-part Michael Jordan documentary "The Last Dance" is here.

Latest updates, full schedule NBA experts on MJ's greatness Big moments from the premiere How to get ready for the doc

Spears: Magic Johnson, due to his ability to play four positions at an elite level, his ability to make everyone better, his leadership, his five championships and his shots in big games. Magic was the main reason the NBA grew into a giant before the Jordan explosion. Michael Jordan was the best scorer. Perhaps Bill Russell was the best defender. But overall, Magic was the best.

Pelton: By the definition I laid out in the previous question, it's LeBron, who has added another MVP-caliber season since I wrote about the Jordan-LeBron debate in the spring of 2018. Because he entered the NBA directly out of high school and never stepped away in his prime like Jordan, James gave his teams more great seasons. That is reflected by his record 12 All-NBA first team selections, as compared to 10 for Jordan, with one more surely in store whenever this unprecedented season concludes.

Arnovitz: Jordan. No matter which metric you prefer -- hard quant, traditional numbers, eye test, team dominance, stylistic influence, cultural impact -- Jordan rates at or near the top.

Marks: Jordan. I grew up a Knicks fan, and it felt like Jordan was superman each time he stepped on the court during those Bulls-Knicks playoff series. In 1998, I had an up-front seat to the first-round playoff series between the Bulls and Nets, and it felt automatic every time the ball left Jordan's hands.

Spears: A cancellation due to the coronavirus pandemic might affect LeBron James' final legacy, because it could take away a potential championship that would add to his cause, but the LA Clippers, Milwaukee Bucks and other teams would beg to differ on that argument. Either way, James already is in the GOAT discussion without question.

Arnovitz: Fiction. The modern NBA extends back for more than 70 seasons. Five weeks of basketball and, possibly, a postseason being canceled would be a blip in the historical sweep of the league and any conversation about its most distinguished players.

MacMullan: Fiction. It doesn't significantly alter the GOAT debate, but I'm sure fans of LeBron would feel cheated -- and they should. There's every reason to believe he had a chance to win his fourth ring, which would have inched him closer to Jordan's mother lode. But ring totals shouldn't be the only criteria -- if so, Russell would be everybody's choice.

Pelton: Given I've already picked LeBron as the GOAT, not really for me. I do think for the rest of the world, James' leading a third different team to a title would be an important validation of his career. From that standpoint, it would matter, and possibly significantly so.

Marks: Fiction. What LeBron has accomplished in his career is exceptional. But while James was on track to contend for his fourth championship this spring with the Lakers, nobody will top what Jordan accomplished in the '80s and '90s.

Arnovitz: Fact. Only two NBA players in history won a pair of MVP awards by the age of 25 -- Kareem and LeBron. Antetokounmpo likely will be the third. Whatever holes exist in his game or rsum at the present moment, there's ample time for Antetokounmpo to crack the code and situate himself squarely in that conversation.

MacMullan: Fact. Who knows what the future brings? Before his Achilles injury, I would have argued the versatile Kevin Durant had a chance at establishing himself as the best. Now, we'll see. Can we accurately forecast Zion Williamson or Luka Doncic so early in their careers? They both look like generational players to me, but can either evolve into the GOAT? Only time will tell.

Spears: Giannis has the ability to get into that conversation as he continues to grow as a player. The only thing he is lacking as a player is a 3-point shot, which will continue to grow.

Marks: Fiction. Giannis likely will win another MVP, but he doesn't have the full body of work, especially in the playoffs, to enter the conversation. The closest player under 30 is Kawhi Leonard, who has two championships and plays at an All-NBA level on both ends. It's hard for me to put Leonard in the GOAT debate, though, without knowing how his body will hold up for the rest of his career. Don't forget that Jordan played all 82 games nine times in his career. The most Leonard has played in a season is 74.

Pelton: It's certainly plausible for Antetokounmpo. And while he's got a lot more work to go, I think it's in the realm of possibility for Doncic, who was putting together one of the best age-20 seasons ever.

Original post:
NBA GOAT debate - Big questions on Michael Jordan and the greatest players ever - ESPN

In countries like South Korea, even though more women were tested positive for Covid-19, more men have died due to the deadly disease.(Photo: Reuters)

When it comes to fighting the deadly novel coronavirus which has killed over 2 million people globally, worldwide data suggest that the mortality rate is much higher in men than women.

In an exclusive interview to India Today, Dr Sharon Moalem, a Canadian-born physician and rare disease specialist, explained why women fared better in fighting Covid-19 than men.

"Females have two X chromosomes whereas males have one X and one Y chromosome. X chromosomes are necessary for survival and contain important genes related to the brain. Y chromosomes, on the other hand, are found only in males and are not crucial for survival. Men are more biologically fragile due to this," Dr Sharon Moalem, who is also the author of 'The Better Half: On the Genetic Superiority of Women' said.

In countries like South Korea, even though more women were tested positive for Covid-19, more men have died due to the disease.

"Men have more muscle mass and more physical strength and that doesn't mean longevity or long life. However, women -- who have XX chromosome --- are born with the advantage of longevity," Dr Moalem said.

'Men are biologically more fragile'

According to Dr Moalem, another reason why women are genetically tougher than men is that they have stronger immune systems due to the presence of estrogen in their body.

"Women, along with double XX chromosome power, also have hormones in their body like estrogen which is good for immunity. Men have testosterone which reduces immunity further. Men are more biologically fragile," Dr Moalem said.

Traditionally, women have always fared better than men when fighting an infection or famine. Women also fight cancer better, Dr Moalem said.

"This is because women have the power of double X power. This gives the female an advantage from the day they are born," Dr Moalem said.

View post:
Why coronavirus is killing more men than women | Expert explains - India Today

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-market-to-2027---global-analysis-and-forecasts-by-type-treatment-application-end-user-and-geography-301041155.html

SOURCE Reportlinker

Follow this link:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Yahoo Finance

Analysis Report on Canine Stem Cell Therapy Market

A report on global Canine Stem Cell Therapy market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Canine Stem Cell Therapy Market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Some key points of Canine Stem Cell Therapy Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Canine Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Canine Stem Cell Therapy Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Canine Stem Cell Therapy market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Canine Stem Cell Therapy market is analyzed and depicted in the report.

The global Canine Stem Cell Therapy market segment by manufacturers include

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Canine Stem Cell Therapy economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Benefits of Purchasing Canine Stem Cell Therapy Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read this article:
Potential impact of coronavirus outbreak on Canine Stem Cell Therapy Market Size, Top Manufacturers, Product Types, Applications and Specification,...

Allosource

Stem Cell Therapy Market: Competitive Landscape

The last chapter of the Stem Cell Therapy market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Stem Cell Therapy Market: Drivers and Restraints

The report explains the drivers of the future of the Stem Cell Therapy market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Stem Cell Therapy market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Stem Cell Therapy market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Stem Cell Therapy Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Stem Cell Therapy market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Stem Cell Therapy market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Stem Cell Therapy market by type and consumption forecasts for the Stem Cell Therapy market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Stem Cell Therapy market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

Rich Mineral Paper Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

More:
Stem Cell Therapy Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports - Cole of Duty

This is a list of all Biotechnology ETFs traded in the USA which are currently tagged by ETF Database. Please note that the list may not contain newly issued ETFs. If youre looking for a more simplified way to browse and compare ETFs, you may want to visit our ETFdb.com Categories, which categorize every ETF in a single best fit category.

* Assets and Average Volume as of 2020-04-17 20:21 UTC

This page includes historical return information for all Biotechnology ETFs listed on U.S. exchanges that are currently tracked by ETF Database.

The table below includes fund flow data for all U.S. listed Biotechnology ETFs. Total fund flow is the capital inflow into an ETF minus the capital outflow from the ETF for a particular time period.

Fund Flows in millions of U.S. Dollars.

The following table includes expense data and other descriptive information for all Biotechnology ETFs listed on U.S. exchanges that are currently tracked by ETF Database. In addition to expense ratio and issuer information, this table displays platforms that offer commission-free trading for certain ETFs.

Clicking on any of the links in the table below will provide additional descriptive and quantitative information on Biotechnology ETFs.

The following table includes ESG Scores and other descriptive information for all Biotechnology ETFs listed on U.S. exchanges that are currently tracked by ETF Database. Easily browse and evaluate ETFs by visiting our ESG Investing themes section and find ETFs that map to various environmental, social, governance and morality themes.

This page includes historical dividend information for all Biotechnology ETFs listed on U.S. exchanges that are currently tracked by ETF Database. Note that certain ETPs may not make dividend payments, and as such some of the information below may not be meaningful.

The table below includes basic holdings data for all U.S. listed Biotechnology ETFs that are currently tagged by ETF Database. The table below includes the number of holdings for each ETF and the percentage of assets that the top ten assets make up, if applicable. For more detailed holdings information for any ETF, click on the link in the right column.

The following table includes certain tax information for all Biotechnology ETFs listed on U.S. exchanges that are currently tracked by ETF Database, including applicable short-term and long-term capital gains rates and the tax form on which gains or losses in each ETF will be reported.

This page contains certain technical information for all Biotechnology ETFs that are listed on U.S. exchanges and tracked by ETF Database. Note that the table below only includes limited technical indicators; click on the View link in the far right column for each ETF to see an expanded display of the products technicals.

This page provides links to various analysis for all Biotechnology ETFs that are listed on U.S. exchanges and tracked by ETF Database. The links in the table below will guide you to various analytical resources for the relevant ETF, including an X-ray of holdings, official fund fact sheet, or objective analyst report.

This page provides ETFdb Ratings for all Biotechnology ETFs that are listed on U.S. exchanges and tracked by ETF Database. The ETFdb Ratings are transparent, quant-based evaluations of ETFs relative to other products in the same ETFdb.com Category. As such, it should be noted that this page may include ETFs from multiple ETFdb.com Categories.

See the rest here:
Top 17 Biotechnology ETFs - ETF Database